Clinical Trial Update: Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial update for AVB-620 in women with primary breast cancer undergoing surgery has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Carcinoma Ductal Breast
• Carcinoma of Breast

Drugs mentioned

• AVB-620

Snippet

Sponsor: Avelas Biosciences, Inc. | Conditions: Primary Invasive Malignant Neoplasm of Female Breast, Carcinoma Breast | Phase 2 | Status: COMPLETED